A clinical study of MK-0482 alone and with pembrolizumab to treat different types of advanced cancer caused by solid tumors (MK-0482-001)

Protocol title: A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors

Why is this study needed?

Researchers are looking for new ways to treat advanced cancer caused by solid tumors. Advanced means cancer has spread from where it started to other parts of the body (**metastatic**) or cannot be removed by surgery**.**

Researchers want to know if giving **MK-0482** (the study medicine) either alone, with **pembrolizumab,** or with **pembrolizumab** and **chemotherapy** can treat advanced solid tumors and 5 certain cancers (brain, breast, pancreatic, lung, and soft tissue). MK-0482 and pembrolizumab are **immunotherapies**, which are treatments that help the immune system fight cancer. Chemotherapy is a treatment that uses medicine to shrink or get rid of cancer.

The goal of this study is to learn about:

- The safety of MK-0482 given alone, with pembrolizumab, or with pembrolizumab and chemotherapy
- How well people tolerate the treatments

Who will take part in this study?

About 230 people with advanced cancer will be in this study. They will be age 18 years and older and:

- Have advanced cancer caused by solid tumors
- Had been treated in the past but the cancer got worse
- Did not tolerate or were not able to receive any treatments known to treat the cancer
- Cancer has not spread to their brain or spine

What treatments are being given during the study?

During the study, people will be assigned to receive one or more of these treatments through a needle into a vein as an intravenous (IV) infusion:

- **MK-0482** every 3 weeks
- **Pembrolizumab** every 3 weeks
- **Chemotherapy:** Chemotherapy will be chosen by the type of cancer and given according to the normal schedule for the chemotherapy medicine being used.

How is this study designed?

Each person could be in the study for about 2 years.

This study has 2 parts:
In Part 1, 85 people will receive either**:**

- **MK-0482 alone,** given at different dose levels. Researchers will start with a low dose and check for safety concerns before giving a higher dose.
- **MK-0482 with pembrolizumab.** MK-0482 will be given at different dose levels with a standard dose of pembrolizumab. Researchers will start with a low dose of MK-0482 and check for safety concerns before giving a higher dose.

Researchers will review the safety of MK-0482 alone and with pembrolizumab and decide which dose of MK-0482 to use in Part 2 with the standard dose of pembrolizumab.

In Part 2: 145 people will be put into groups based on the type of cancer they have and receive either:

- **MK-0482 with pembrolizumab**
- **MK-0482 with pembrolizumab and chemotherapy**

Both the people in the study and the researcher will know which study treatment a person is getting (open-label study). During this study, people may give tumor, blood, and urine samples, and have imaging tests, and physical examinations.

What are the goals of this study and how will they be measured?

Main goals	How they will be measured
To learn about the **safety** of MK-0482 given alone or with pembrolizumab and how well people tolerate the treatments in Part 1	Number of people in Part 1 who: • Had a medical problem related to MK-0482 during the first 3 weeks of Part 1 that prevented an increase in dose (**dose limiting toxicity**) • Had an **adverse event (AE)**. An AE is a health problem that happens or worsens during a study. • Stopped treatment due to an AE
To learn about the **safety** of MK-0482 given with pembrolizumab or with pembrolizumab and chemotherapy and how well people tolerate the treatments in Part 2	Number of people in Part 2 who: • Had a medical problem related to MK-0482 during the first 3 weeks of Part 2 that prevented an increase in dose (**dose limiting toxicity**) only for people who receive MK-0482 with pembrolizumab and chemotherapy • Had an **AE** • Stopped treatment due to an AE
Other goal	**How it will be measured**
To compare what happens to different doses of MK-0482 given alone or with pembrolizumab in a person's body over time in Part 1	During Part 1, researchers will measure the amount of MK-0482 in people's blood samples.
To learn the **objective response rate (ORR)** of people with different types of cancer who receive MK-0482 given with pembrolizumab or with pembrolizumab and chemotherapy in Part 2	ORR is the number of people whose cancer responds to treatment (the cancer gets smaller or goes away) during Part 2 of the study.

What are the possible benefits and risks?

People may or may not benefit from the treatment received during the study. More information about the benefits and risks is in the Investigator Brochure, Protocol, and Informed Consent documents.